New Data from IBD Subgroup Analysis
Demonstrates Improved Outcomes for Crohn's Disease Patients
DURHAM,
N.C., May 17, 2024 /PRNewswire/
-- Real-world evidence leader, Target RWE, Real-world
evidence leader Target RWE today announced a major expansion of its
TARGET-GASTRO longitudinal registry, now 30,000+ patients strong,
ahead of Digestive Disease Week (DDW) in Washington, D.C., May
18-21. The expansion builds on the recently announced
partnership with the American Gastroenterological Association (AGA)
which aims to validate disease severity scores from real-world data
on patients with high unmet medical need gastrointestinal (GI)
diseases, such as EoE and EGID's.
TARGET-GASTRO has enrolled patients with GI diseases including
eosinophilic esophagitis (EoE) and other eosinophilic
gastrointestinal diseases (EGIDs), inflammatory bowel disease
(Crohn's disease and ulcerative colitis), Clostridioides difficile
(C. diff) infection (CDI), and celiac disease (CeD), with an
average of 42 months of patient follow-up. The large sample size of
each of these groups enable Target RWE to conduct advanced
analytics on subpopulations of interest. This includes collective
measures that fully contextualize patient journeys,
relevant variables, and endpoints within unique subpopulations
for GI conditions of growing prevalence and concern.
The initial partnership with AGA allows Target RWE to expand its
insights on patients with EGIDs. Target RWE is working with AGA and
a group of thought leaders to validate the Index of Severity for
EoE (I-SEE) in the real world. The powerful combination of tools
like the I-SEE with real world, longitudinal data from
TARGET-GASTRO will help inform how emerging treatment options for
EoE are optimized and improve patient care.
Separately, TARGET-IBD research was recently accepted for
publication in the peer-reviewed Journal of Clinical
Gastroenterology, "Factors Predicting Loss of Remission in
Crohn's Disease Patients in Endoscopic Remission in the Real World:
Results from TARGET-IBD." This study found that active histologic
inflammation, despite endoscopic remission, was independently
associated with risk of subsequent loss of remission (LOR),
suggesting that histologic remission may improve outcomes in
Crohn's disease (CD). TARGET-IBD is a longitudinal, observational
cohort study under the TARGET-GASTRO protocol.
Other findings on factors related to loss of remission in CD
include:
- Of 658 CD patients with steroid-free endoscopic remission, the
majority were female (57%), white (83%), non-Hispanic (93%); 20%
had ileal and 20% isolated colonic disease. Inflammatory (B1)
disease was the most common phenotype (43%).
- Of these 658, 257 (39%) had histologic inflammation on index
colonoscopy. Histologic inflammation at index colonoscopy was
associated with nearly twice the LOR risk (HR 1.96, 95% CI
1.50-2.57) with median time to relapse of 1.20 years. Biologic use
at index was associated with lower LOR risk (monotherapy, HR 0.61,
95% CI 0.45-0.82; combination therapy, HR 0.43, 95% CI
0.28-0.66).
"Understanding associations between treatment targets in CD and
longer-term patient outcomes informs decisions on prognosis and
treatment modification. This research demonstrated that histologic
inflammation, despite endoscopic remission was associated with risk
of subsequent loss of remission, an important finding," said study
author and co-chair of TARGET-IBD, Millie
D. Long, MD, MPH. Dr. Long is a professor of medicine in the
division of gastroenterology and hepatology at the University of North Carolina School of Medicine,
Chapel Hill.
"TARGET-GASTRO is a rich and growing dataset to help track
serious GI diseases that are increasing in prevalence. With the
integration of the AGA's I-SEE tool in combination with our
advanced analytics, we are helping inform important treatment
pathways for countless patients. As TARGET-IBD and TARGET-GASTRO
continue to expand, we look forward to applying these tools to
improve patient care," said Michael W.
Fried, MD, FAASLD, Co-Founder and Chief Medical Officer of
Target RWE.
Follow us on X (@TargetRWE) and LinkedIn to keep up with the
latest news!
About Target RWE
As the industry's best-in-class, complete real-world evidence
(RWE) solution, Target RWE is a distinctly collaborative enterprise
that unifies real-world data (RWD) sets and advanced RWE analytics
in an integrated community, shifting the paradigm in healthcare for
how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple
therapeutic areas representing granular data from diverse patients
in academic and community settings. Our rigorous, interactive, and
advanced RWE analytics extract deep insights from RWD to answer
important questions in healthcare. Target RWE brings together the
brightest minds in healthcare through an unmatched community of key
opinion leaders, patients, and healthcare stakeholders in a
collaborative and dynamic model. www.targetrwe.com
Contact:
Kayla Slake
Senior Marketing Manager
kslake@targetrwe.com
984.234.0268 ext 205
View original content to download
multimedia:https://www.prnewswire.com/news-releases/real-world-evidence-leader-in-inflammatory-bowel-disease-target-rwe-announces-expanded-footprint-with-target-gastro-registry-of-30-000-patients-at-digestive-disease-week-302148870.html
SOURCE Target RWE